ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Cuproptosis and Mitophagy Mediated by the THUMPD1/IGF2R-Dependent Suppression of AKT and Activation of AMPK Signaling Suppress Lung Adenocarcinoma Progression.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Lung adenocarcinoma (LUAD) remains a leading cause of cancer-related mortality. N4-acetylcytidine (ac4C) modification regulates mRNA stability and translation, but the role of its associated co-factor, THUMP domain-containing protein 1 (THUMPD1), in cancer is unknown. Clinical LUAD samples and Gene Expression Omnibus (GEO) datasets were analyzed for THUMPD1 expression and prognosis. In vitro and in vivo functional assays were performed to assess the impact of THUMPD1 on LUAD. Multi-omics approaches and mechanistic studies were employed to identify downstream targets and signaling pathways. THUMPD1 was significantly downregulated in advanced-stage LUAD. THUMPD1 acted as a tumor suppressor, inhibiting LUAD cell proliferation, metastasis, and tumor growth in mouse models. Mechanistically, THUMPD1 directly bound to and upregulated the translation of insulin-like growth factor 2 receptor (IGF2R) mRNA in an ac4C-independent manner by facilitating its cytoplasmic localization. The THUMPD1-IGF2R axis inhibited AKT signaling, which in turn led to the activation of AMPK. This resulted in intracellular Cu
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.